{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:44:39Z","timestamp":1794980679499,"version":"4.9.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioblastoma (GBM) remains the most lethal malignant tumours. Gboxin, an oxidative phosphorylation inhibitor, specifically restrains GBM growth by inhibiting the activity of F<jats:sub>0<\/jats:sub>F<jats:sub>1<\/jats:sub> ATPase complex V. However, its anti-GBM effect is seriously limited by poor blood circulation, the blood brain barrier (BBB) and non-specific GBM tissue\/cell uptake, leading to insufficient Gboxin accumulation at GBM sites, which limits its further clinical application. Here we present a biomimetic nanomedicine (HM-NPs@G) by coating cancer cell-mitochondria hybrid membrane (HM) on the surface of Gboxin-loaded nanoparticles. An additional design element uses a reactive oxygen species responsive polymer to facilitate at-site Gboxin release. The HM camouflaging endows HM-NPs@G with unique features including good biocompatibility, improved pharmacokinetic profile, efficient BBB permeability and homotypic dual tumour cell and mitochondria targeting. The results suggest that HM-NPs@G achieve improved blood circulation (4.90\u2009h <jats:italic>versus<\/jats:italic> 0.47\u2009h of free Gboxin) and tumour accumulation (7.73% ID\/g <jats:italic>versus<\/jats:italic> 1.06% ID\/g shown by free Gboxin). Effective tumour inhibition in orthotopic U87MG GBM and patient derived X01 GBM stem cell xenografts in female mice with extended survival time and negligible side effects are also noted. We believe that the biomimetic Gboxin nanomedicine represents a promising treatment for brain tumours with clinical potential.<\/jats:p>","DOI":"10.1038\/s41467-023-40280-3","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T13:01:47Z","timestamp":1690549307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-1376","authenticated-orcid":false,"given":"Yan","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2370-0779","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-3163","authenticated-orcid":false,"given":"Bingyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"40280_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrclinonc.2017.122","volume":"14","author":"P Sidaway","year":"2017","unstructured":"Sidaway, P. Glioblastoma subtypes revisited. Nat. Rev. Clin. Oncol. 14, 587\u2013587 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"40280_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nature09624","volume":"468","author":"R Wang","year":"2010","unstructured":"Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829\u2013833 (2010).","journal-title":"Nature"},{"key":"40280_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JCO.19.00367","volume":"38","author":"K Draaisma","year":"2019","unstructured":"Draaisma, K. et al. Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study. J. Clin. Oncol. 38, 81\u201399 (2019).","journal-title":"J. Clin. Oncol."},{"key":"40280_CR4","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.3390\/cancers12102883","volume":"12","author":"SS Stylli","year":"2020","unstructured":"Stylli, S. S. Novel treatment strategies for glioblastoma. Cancers 12, 2883 (2020).","journal-title":"Cancers"},{"key":"40280_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","volume":"147","author":"L Marenco-Hillembrand","year":"2020","unstructured":"Marenco-Hillembrand, L. et al. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J. Neurooncol. 147, 297\u2013307 (2020).","journal-title":"J. Neurooncol."},{"key":"40280_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41586-019-0993-x","volume":"567","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature 567, 341\u2013346 (2019).","journal-title":"Nature"},{"key":"40280_CR7","doi-asserted-by":"publisher","first-page":"119491","DOI":"10.1016\/j.biomaterials.2019.119491","volume":"224","author":"J Xie","year":"2019","unstructured":"Xie, J. et al. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials 224, 119491 (2019).","journal-title":"Biomaterials"},{"key":"40280_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/10717544.2019.1616235","volume":"26","author":"D Wang","year":"2019","unstructured":"Wang, D. et al. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain\/brain tumor barriers for glioblastoma treatment. Drug Deliv. 26, 551\u2013565 (2019).","journal-title":"Drug Deliv."},{"key":"40280_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature15373","volume":"526","author":"CM Hu","year":"2015","unstructured":"Hu, C. M. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118\u2013121 (2015).","journal-title":"Nature"},{"key":"40280_CR10","doi-asserted-by":"publisher","first-page":"eaba6137","DOI":"10.1126\/scirobotics.aba6137","volume":"5","author":"S Tang","year":"2020","unstructured":"Tang, S. et al. Enzyme-powered Janus platelet cell robots for active and targeted drug delivery. Sci. Robot 5, eaba6137 (2020).","journal-title":"Sci. Robot"},{"key":"40280_CR11","doi-asserted-by":"publisher","first-page":"eaaz6108","DOI":"10.1126\/sciadv.aaz6108","volume":"6","author":"J Zhuang","year":"2020","unstructured":"Zhuang, J. et al. Targeted gene silencing in vivo by platelet membrane\u2013coated metal-organic framework nanoparticles. Sci. Adv. 6, eaaz6108 (2020).","journal-title":"Sci. Adv."},{"key":"40280_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nnano.2013.54","volume":"8","author":"CM Hu","year":"2013","unstructured":"Hu, C. M. et al. A biomimetic nanosponge that absorbs pore-forming toxins. Nat. Nanotechnol. 8, 336\u2013340 (2013).","journal-title":"Nat. Nanotechnol."},{"key":"40280_CR13","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1073\/pnas.1106634108","volume":"108","author":"CM Hu","year":"2011","unstructured":"Hu, C. M. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980\u201310985 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"40280_CR14","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.1021\/acsnano.2c00320","volume":"16","author":"W He","year":"2022","unstructured":"He, W. et al. Brain-targeted codelivery of Bcl-2\/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy. ACS Nano 16, 6293\u20136308 (2022).","journal-title":"ACS Nano"},{"key":"40280_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nnano.2017.54","volume":"12","author":"J Xue","year":"2017","unstructured":"Xue, J. et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 12, 692\u2013700 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"40280_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16439-7","volume":"11","author":"C Gao","year":"2020","unstructured":"Gao, C. et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat. Commun. 11, 2622 (2020).","journal-title":"Nat. Commun."},{"key":"40280_CR17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/s41565-018-0254-4","volume":"13","author":"Q Zhang","year":"2018","unstructured":"Zhang, Q. et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat. Nanotechnol. 13, 1182\u20131190 (2018).","journal-title":"Nat. Nanotechnol."},{"key":"40280_CR18","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1021\/acs.nanolett.0c01503","volume":"20","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. Unraveling cell-type-specific targeted delivery of membrane-camouflaged nanoparticles with plasmonic imaging. Nano Lett. 20, 5228\u20135235 (2020).","journal-title":"Nano Lett."},{"key":"40280_CR19","doi-asserted-by":"publisher","first-page":"e2004853","DOI":"10.1002\/adma.202004853","volume":"32","author":"L Rao","year":"2020","unstructured":"Rao, L. et al. Activating macrophage-mediated cancer immunotherapy by genetically edited nanoparticles. Adv. Mater. 32, e2004853 (2020).","journal-title":"Adv. Mater."},{"key":"40280_CR20","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1002\/smll.201600624","volume":"12","author":"C Gao","year":"2016","unstructured":"Gao, C. et al. Stem cell membrane-coated nanogels for highly efficient in vivo tumor targeted drug delivery. Small 12, 4056\u20134062 (2016).","journal-title":"Small"},{"key":"40280_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10562-w","volume":"10","author":"C Qiu","year":"2019","unstructured":"Qiu, C. et al. Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes. Nat. Commun. 10, 2702 (2019).","journal-title":"Nat. Commun."},{"key":"40280_CR22","doi-asserted-by":"publisher","first-page":"1803531","DOI":"10.1002\/adfm.201803531","volume":"28","author":"L Rao","year":"2018","unstructured":"Rao, L. et al. Platelet-leukocyte hybrid membrane-coated immunomagnetic beads for highly efficient and highly specific isolation of circulating tumor cells. Adv. Funct. Mater. 28, 1803531 (2018).","journal-title":"Adv. Funct. Mater."},{"key":"40280_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-021-00631-2","volume":"6","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Sig Transduct. Target Ther. 6, 225 (2021).","journal-title":"Sig Transduct. Target Ther."},{"key":"40280_CR24","doi-asserted-by":"publisher","first-page":"114006","DOI":"10.1016\/j.addr.2021.114006","volume":"179","author":"N Krishnan","year":"2021","unstructured":"Krishnan, N. et al. Engineering of stimuli-responsive self-assembled biomimetic nanoparticles. Adv. Drug Deliv. Rev. 179, 114006 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"40280_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nnano.2012.212","volume":"8","author":"A Parodi","year":"2013","unstructured":"Parodi, A. et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8, 61\u201368 (2013).","journal-title":"Nat. Nanotechnol."},{"key":"40280_CR26","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1021\/acs.nanolett.9b04683","volume":"20","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy. Nano Lett. 20, 1637\u20131646 (2020).","journal-title":"Nano Lett."},{"key":"40280_CR27","doi-asserted-by":"publisher","first-page":"e1803717","DOI":"10.1002\/adma.201803717","volume":"30","author":"Y Zou","year":"2018","unstructured":"Zou, Y. et al. Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine. Adv. Mater. 30, e1803717 (2018).","journal-title":"Adv. Mater."},{"key":"40280_CR28","doi-asserted-by":"publisher","first-page":"9581","DOI":"10.1002\/adma.201602173","volume":"28","author":"H Sun","year":"2016","unstructured":"Sun, H. et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv. Mater. 28, 9581\u20139588 (2016).","journal-title":"Adv. Mater."},{"key":"40280_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.18632\/oncotarget.872","volume":"4","author":"K Chu","year":"2013","unstructured":"Chu, K. et al. The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism. Oncotarget 4, 446\u2013462 (2013).","journal-title":"Oncotarget"},{"key":"40280_CR30","doi-asserted-by":"publisher","first-page":"2203958","DOI":"10.1002\/adma.202203958","volume":"34","author":"Y Zou","year":"2022","unstructured":"Zou Y, et al. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Adv. Mater. 34, 2203958 (2022).","journal-title":"Adv. Mater."},{"key":"40280_CR31","doi-asserted-by":"publisher","first-page":"15473","DOI":"10.1039\/D0NR04212A","volume":"12","author":"YZ Zhao","year":"2020","unstructured":"Zhao, Y. Z. et al. Tumor cellular membrane camouflaged liposomes as a non-invasive vehicle for genes: specific targeting toward homologous gliomas and traversing the blood-brain barrier. Nanoscale 12, 15473\u201315494 (2020).","journal-title":"Nanoscale"},{"key":"40280_CR32","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s12272-010-1114-4","volume":"33","author":"HJ Kim","year":"2010","unstructured":"Kim, H. J. et al. NecroX as a novel class of mitochondrial reactive oxygen species and ONOO\u2212 scavenger. Arch. Pharm. Res. 33, 1813\u20131823 (2010).","journal-title":"Arch. Pharm. Res."},{"key":"40280_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1039\/C8PY01504J","volume":"10","author":"Y Tan","year":"2019","unstructured":"Tan, Y. et al. In vivoprogramming of tumor mitochondria-specific doxorubicin delivery by a cationic glycolipid polymer for enhanced antitumor activity. Polym. Chem. 10, 512\u2013525 (2019).","journal-title":"Polym. Chem."},{"key":"40280_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/EXP.20210149","volume":"1","author":"H Huang","year":"2021","unstructured":"Huang, H. et al. Mitochondria-specific nanocatalysts for chemotherapy-augmented sequential chemoreactive tumor therapy. Exploration 1, 50\u201360 (2021).","journal-title":"Exploration"},{"key":"40280_CR35","doi-asserted-by":"publisher","first-page":"20210115","DOI":"10.1002\/EXP.20210115","volume":"1","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Mitochondria-targeted nanoparticles in treatment of neurodegenerative diseases. Exploration 1, 20210115 (2021).","journal-title":"Exploration"},{"key":"40280_CR36","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1021\/acsnano.7b08355","volume":"12","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Erythrocyte-cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal\/chemotherapy of melanoma. ACS Nano 12, 5241\u20135252 (2018).","journal-title":"ACS Nano"},{"key":"40280_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31799-y","volume":"13","author":"G Lu","year":"2022","unstructured":"Lu, G. et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat. Commun. 13, 4214 (2022).","journal-title":"Nat. Commun."},{"key":"40280_CR38","doi-asserted-by":"publisher","first-page":"e2006484","DOI":"10.1002\/smll.202006484","volume":"17","author":"F Oroojalian","year":"2021","unstructured":"Oroojalian, F. et al. Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy. Small 17, e2006484 (2021).","journal-title":"Small"},{"key":"40280_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tcb.2020.09.008","volume":"31","author":"S Gao","year":"2021","unstructured":"Gao, S. et al. Mitochondrial fusion: the machineries in and out. Trends Cell Biol. 31, 62\u201374 (2021).","journal-title":"Trends Cell Biol."},{"key":"40280_CR40","doi-asserted-by":"publisher","first-page":"e9863","DOI":"10.1073\/pnas.1708782114","volume":"114","author":"X Huang","year":"2017","unstructured":"Huang, X. et al. Sequences flanking the transmembrane segments facilitate mitochondrial localization and membrane fusion by mitofusin. Proc. Natl Acad. Sci. USA 114, e9863\u2013e9872 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"40280_CR41","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1063\/1.455064","volume":"89","author":"GA Petersson","year":"1988","unstructured":"Petersson, G. A. et al. A complete basis set model chemistry. I. The total energies of closed\u2010shell atoms and hydrides of the first\u2010row elements. J. Chem. Phys. 89, 2193\u20132218 (1988).","journal-title":"J. Chem. Phys."},{"key":"40280_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","volume":"143","author":"ND Donahue","year":"2019","unstructured":"Donahue, N. D. et al. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliv. Rev. 143, 68\u201396 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"40280_CR43","doi-asserted-by":"publisher","first-page":"2004025","DOI":"10.1002\/advs.202004025","volume":"8","author":"S Ruan","year":"2021","unstructured":"Ruan, S. et al. Rethinking CRITID procedure of brain targeting drug delivery: Circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release. Adv. Sci. 8, 2004025 (2021).","journal-title":"Adv. Sci."},{"key":"40280_CR44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nature12985","volume":"505","author":"JR Friedman","year":"2014","unstructured":"Friedman, J. R. et al. Mitochondrial form and function. Nature 505, 335\u2013343 (2014).","journal-title":"Nature"},{"key":"40280_CR45","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1021\/acsnano.1c09456","volume":"16","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Potential-independent intracellular drug delivery and mitochondrial targeting. ACS Nano 16, 1409\u20131420 (2022).","journal-title":"ACS Nano"},{"key":"40280_CR46","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.7150\/thno.40395","volume":"10","author":"H Yu","year":"2020","unstructured":"Yu, H. et al. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. Theranostics 10, 2342\u20132357 (2020).","journal-title":"Theranostics"},{"key":"40280_CR47","doi-asserted-by":"publisher","first-page":"1901690","DOI":"10.1002\/advs.201901690","volume":"6","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Janus nanobullets combine photodynamic therapy and magnetic hyperthermia to potentiate synergetic anti-metastatic immunotherapy. Adv. Sci. 6, 1901690 (2019).","journal-title":"Adv. Sci."},{"key":"40280_CR48","doi-asserted-by":"publisher","first-page":"1706759","DOI":"10.1002\/adma.201706759","volume":"30","author":"RH Fang","year":"2018","unstructured":"Fang, R. H. et al. Cell membrane coating nanotechnology. Adv. Mater. 30, 1706759 (2018).","journal-title":"Adv. Mater."},{"key":"40280_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.biomaterials.2019.04.026","volume":"211","author":"J Lai","year":"2019","unstructured":"Lai, J. et al. Scaffolds biomimicking macrophages for a glioblastoma NIR-Ib imaging guided photothermal therapeutic strategy by crossing Blood-Brain Barrier. Biomaterials 211, 48\u201356 (2019).","journal-title":"Biomaterials"},{"key":"40280_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D. et al. The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26\u201341 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"40280_CR51","doi-asserted-by":"publisher","first-page":"1909369","DOI":"10.1002\/adfm.201909369","volume":"30","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. Camouflaging nanoparticles with brain metastatic tumor cell membranes: a new strategy to traverse blood\u2013brain barrier for imaging and therapy of brain tumors. Adv. Funct. Mater. 30, 1909369 (2020).","journal-title":"Adv. Funct. Mater."},{"key":"40280_CR52","doi-asserted-by":"publisher","first-page":"119793","DOI":"10.1016\/j.biomaterials.2020.119793","volume":"237","author":"L Wen","year":"2020","unstructured":"Wen, L. et al. AKT activation by SC79 to transiently re-open pathological blood brain barrier for improved functionalized nanoparticles therapy of glioblastoma. Biomaterials 237, 119793 (2020).","journal-title":"Biomaterials"},{"key":"40280_CR53","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1021\/acsnano.9b04397","volume":"13","author":"G Morad","year":"2019","unstructured":"Morad, G. et al. Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano 13, 13853\u201313865 (2019).","journal-title":"ACS Nano"},{"key":"40280_CR54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12031-011-9496-4","volume":"44","author":"H Jiao","year":"2011","unstructured":"Jiao, H. et al. Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood\u2013brain barrier in a focal cerebral ischemic insult. J. Mol. Neurosci. 44, 130\u2013139 (2011).","journal-title":"J. Mol. Neurosci."},{"key":"40280_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neulet.2018.11.022","volume":"694","author":"I Kimura","year":"2019","unstructured":"Kimura, I. et al. Activation of the \u03b17 nicotinic acetylcholine receptor upregulates blood-brain barrier function through increased claudin-5 and occludin expression in rat brain endothelial cells. Neurosci. Lett. 694, 9\u201313 (2019).","journal-title":"Neurosci. Lett."},{"key":"40280_CR56","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1021\/acsnano.2c07264","volume":"17","author":"M Son","year":"2023","unstructured":"Son, M. et al. Molecular recognition and in vivo detection of temozolomide and 5-aminoimidazole-4-carboxamide for glioblastoma using near-infrared fluorescent carbon nanotube sensors. ACS Nano 17, 240\u2013250 (2023).","journal-title":"ACS Nano"},{"key":"40280_CR57","doi-asserted-by":"publisher","first-page":"eabl4923","DOI":"10.1126\/sciadv.abl4923","volume":"8","author":"R Shi","year":"2022","unstructured":"Shi, R. et al. High-throughput glycolytic inhibitor discovery targeting glioblastoma by graphite dots-assisted LDI mass spectrometry. Sci. Adv. 8, eabl4923 (2022).","journal-title":"Sci. Adv."},{"key":"40280_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13948-y","volume":"11","author":"BG Lui","year":"2020","unstructured":"Lui, B. G. et al. Targeting the tumor vasculature with engineered cystine-knot miniproteins. Nat. Commun. 11, 295 (2020).","journal-title":"Nat. Commun."},{"key":"40280_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10415-6","volume":"10","author":"WS Kim","year":"2019","unstructured":"Kim, W. S. et al. A synthesis strategy for tetracyclic terpenoids leads to agonists of ER\u03b2. Nat. Commun. 10, 2448 (2019).","journal-title":"Nat. Commun."},{"key":"40280_CR60","doi-asserted-by":"publisher","first-page":"e202214786","DOI":"10.1002\/anie.202214786","volume":"61","author":"X Liang","year":"2022","unstructured":"Liang, X. et al. Ruthenium-catalyzed butadiene-mediated crotylation and oxazaborolidine-catalyzed vinylogous mukaiyama aldol reaction for the synthesis of C1-C19 and C23-C35 of neaumycin B. Angew. Chem. Int Ed. Engl. 61, e202214786 (2022).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"40280_CR61","doi-asserted-by":"publisher","first-page":"eabm8011","DOI":"10.1126\/sciadv.abm8011","volume":"8","author":"Y Zou","year":"2022","unstructured":"Zou, Y. et al. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci. Adv. 8, eabm8011 (2022).","journal-title":"Sci. Adv."},{"key":"40280_CR62","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-16-2704","volume":"77","author":"SN Chand","year":"2017","unstructured":"Chand, S. N. et al. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors. Cancer Res. 77, 5011\u20135025 (2017).","journal-title":"Cancer Res."},{"key":"40280_CR63","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.18632\/oncotarget.2250","volume":"5","author":"J Yin","year":"2014","unstructured":"Yin, J. et al. CPEB1 modulates differentiation of glioma stem cells via downregulation of HES1 and SIRT1 expression. Oncotarget 5, 6756\u20136769 (2014).","journal-title":"Oncotarget"},{"key":"40280_CR64","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pbio.1002152","volume":"13","author":"J Yin","year":"2015","unstructured":"Yin, J. et al. Pigment Epithelium-derived factor (PEDF) expression induced by EGFRvIII promotes self-renewal and tumor progression of glioma stem cells. PLoS Biol. 13, e1002152 (2015).","journal-title":"PLoS Biol."},{"key":"40280_CR65","unstructured":"Frisch, M. J., et al. Gaussian 16, Revision A.03, Gaussian, Inc., Wallingford CT. (2016)."},{"key":"40280_CR66","doi-asserted-by":"publisher","first-page":"11623","DOI":"10.1021\/j100096a001","volume":"98","author":"PJ Stephens","year":"1994","unstructured":"Stephens, P. J. et al. Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields. J. Phys. Chem. 98, 11623\u201311627 (1994).","journal-title":"J. Phys. Chem."},{"key":"40280_CR67","doi-asserted-by":"publisher","first-page":"32184","DOI":"10.1039\/C7CP04913G","volume":"19","author":"L Goerigk","year":"2017","unstructured":"Goerigk, L. et al. A look at the density functional theory zoo with the advanced GMTKN55 database for general main group thermochemistry, kinetics and noncovalent interactions. Phys. Chem. Chem. Phys. 19, 32184\u201332215 (2017).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"40280_CR68","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1063\/1.460447","volume":"94","author":"GA Petersson","year":"1991","unstructured":"Petersson, G. A. et al. A complete basis set model chemistry. II. Open\u2010shell systems and the total energies of the first\u2010row atoms. J. Chem. Phys. 94, 6081\u20136090 (1991).","journal-title":"J. Chem. Phys."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40280-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40280-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40280-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T13:24:14Z","timestamp":1690550654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40280-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40280"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-40280-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4557"}}